TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in CancerHelsinki, Finland – 31 March 2022: TILT Biotherapeutics, a clinical-stage biotechnology company developing oncolytic immunotherapy for enabling therapies based on T cells, such as immune checkpoint inhibitors a.
TILT Biotherapeutics Announces Data at ESMO on Its Oncolytic Immunotherapy Platform finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that new preclinical data relating to the use of its oncolytic immunotherapy platform
Share:
Swedbank appointed as lead advisor to explore financing options
IND for ovarian cancer trial has been submitted
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer. The trial will evaluate the company s adenoviral cancer immunotherapy TILT-123, a double cytokine armed oncolytic adenovirus, in combination with KEYTRUDA
® (pembrolizumab), MSD s anti-PD-1 therapy, in a dose escalation trial in platinum resistant or refractory ovarian cancer patients.
The trial will include 15 to 30 patients and will be led by Dr. Matt Block at the Mayo Clinic (Minnesota, USA). During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter TILT-123 in conjunction with pembrolizumab. The trial s objective is to evaluate the safety and efficacy of TILT-123 in combination with pembrolizumab and is desig
Press release content from Business Wire. The AP news staff was not involved in its creation.
TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial
May 5, 2021 GMT
HELSINKI, Finland (BUSINESS WIRE) May 5, 2021
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus. The trial is being performed in patients with injectable solid tumors. Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), leading international treatment facilities specializing in diagnostics, treatment and follow-up of cancers.